The stock of Inovio Pharmaceuticals Inc (INO) has gone up by 3.44% for the week, with a -5.30% drop in the past month and a -49.89% drop in the past quarter. The volatility ratio for the week is 5.54%, and the volatility levels for the past 30 days are 7.40% for INO. The simple moving average for the past 20 days is -0.36% for INO’s stock, with a -64.03% simple moving average for the past 200 days.
Is It Worth Investing in Inovio Pharmaceuticals Inc (NASDAQ: INO) Right Now?
Moreover, the 36-month beta value for INO is 1.74. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for INO is 35.85M and currently, short sellers hold a 15.41% of that float. On March 14, 2025, INO’s average trading volume was 943.21K shares.
INO) stock’s latest price update
The stock of Inovio Pharmaceuticals Inc (NASDAQ: INO) has increased by 4.51 when compared to last closing price of 1.93. Despite this, the company has experienced a 3.44% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-13 that Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug Effective target binding: expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72 PLYMOUTH MEETING, Pa., March 13, 2025 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with Stephens repeating the rating for INO by listing it as a “Overweight.” The predicted price for INO in the upcoming period, according to Stephens is $20 based on the research report published on May 14, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see INO reach a price target of $4. The rating they have provided for INO stocks is “Outperform” according to the report published on January 25th, 2024.
INO Trading at -0.77% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.32% of loss for the given period.
Volatility was left at 7.40%, however, over the last 30 days, the volatility rate increased by 5.54%, as shares sank -4.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.04% upper at present.
During the last 5 trading sessions, INO rose by +4.10%, which changed the moving average for the period of 200-days by -81.55% in comparison to the 20-day moving average, which settled at $2.0250. In addition, Inovio Pharmaceuticals Inc saw 10.22% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -587.1 for the present operating margin
- -7.67 for the gross margin
The net margin for Inovio Pharmaceuticals Inc stands at -124147.37. The total capital return value is set at -1.43. Equity return is now at value -106.64, with -75.21 for asset returns.
Based on Inovio Pharmaceuticals Inc (INO), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -6784.78. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -259.53.
Currently, EBITDA for the company is -130.39 million with net debt to EBITDA at 0.08. When we switch over and look at the enterprise to sales, we see a ratio of 315.72. The receivables turnover for the company is 0.11for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.88.
Conclusion
To wrap up, the performance of Inovio Pharmaceuticals Inc (INO) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
